Compare ASTL & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASTL | CBIO |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 389.7M |
| IPO Year | N/A | N/A |
| Metric | ASTL | CBIO |
|---|---|---|
| Price | $4.78 | $8.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.17 |
| AVG Volume (30 Days) | ★ 1.9M | 236.4K |
| Earning Date | 03-11-2026 | 02-18-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,589,572,318.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.02 | $8.72 |
| 52 Week High | $8.28 | $21.40 |
| Indicator | ASTL | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.24 | 29.40 |
| Support Level | $4.27 | $8.72 |
| Resistance Level | $5.37 | $9.69 |
| Average True Range (ATR) | 0.38 | 0.85 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 56.92 | 6.36 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.